<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Telix Pharmaceuticals Ltd — News on 6ix</title>
    <link>https://6ix.com/company/telix-pharmaceuticals-ltd</link>
    <description>Latest news and press releases for Telix Pharmaceuticals Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 23:27:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/telix-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68366ac278dffbe2df15fa35.webp</url>
      <title>Telix Pharmaceuticals Ltd</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd</link>
    </image>
    <item>
      <title>Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/educational-webinar-unlocking-the-potential-of-psma-therapy-a-nextgeneration-portfolio-approach</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/educational-webinar-unlocking-the-potential-of-psma-therapy-a-nextgeneration-portfolio-approach</guid>
      <pubDate>Mon, 27 Apr 2026 23:27:00 GMT</pubDate>
      <description>MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSMA1-targeted radionuclide therapy and Telix’s differentiated, multi-product approach to treating prostate cancer across the disease continuum. Dr. David N. Cade, Telix Group Chief Medical Officer will host a discussion with Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St</description>
    </item>
    <item>
      <title>ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-selected-as-late-breaking-abstract-at-asco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-selected-as-late-breaking-abstract-at-asco-2026</guid>
      <pubDate>Tue, 21 Apr 2026 20:49:00 GMT</pubDate>
      <description>MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL. ProstACT Global is an international, multi-center, Phase 3 trial evaluating Telix’s l</description>
    </item>
    <item>
      <title>Telix Successfully Prices Upsized US$600M Convertible Bonds</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-successfully-prices-upsized-usdollar600m-convertible-bonds</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-successfully-prices-upsized-usdollar600m-convertible-bonds</guid>
      <pubDate>Wed, 15 Apr 2026 02:34:20 GMT</pubDate>
      <description>Telix Successfully Prices Upsized US$600M Convertible Bonds</description>
    </item>
    <item>
      <title>Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-successfully-prices-and-upsizes-usdollar600-million-convertible-bonds</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-successfully-prices-and-upsizes-usdollar600-million-convertible-bonds</guid>
      <pubDate>Tue, 14 Apr 2026 22:35:00 GMT</pubDate>
      <description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (&quot;Telix&quot;) is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the &quot;Issuer&quot;), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. from US$550 million to US$600 million due to strong demand (the &quot;Offering&quot;). The convertible notes, also referred to as &quot;convertible bonds&quot; (&quot;Convertible Bonds&quot;),</description>
    </item>
    <item>
      <title>Telix Investor Presentation April 2026</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-investor-presentation-april-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-investor-presentation-april-2026</guid>
      <pubDate>Tue, 14 Apr 2026 11:29:03 GMT</pubDate>
      <description>Telix Investor Presentation April 2026</description>
    </item>
    <item>
      <title>Telix Refinances Convertible Bonds</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-refinances-convertible-bonds</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-refinances-convertible-bonds</guid>
      <pubDate>Tue, 14 Apr 2026 11:15:03 GMT</pubDate>
      <description>Telix Refinances Convertible Bonds</description>
    </item>
    <item>
      <title>Telix and Regeneron Announce Strategic Radiopharma Collaboration</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-and-regeneron-announce-strategic-radiopharma-collaboration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-and-regeneron-announce-strategic-radiopharma-collaboration-1</guid>
      <pubDate>Mon, 13 Apr 2026 10:30:00 GMT</pubDate>
      <description>Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggre</description>
    </item>
    <item>
      <title>Regeneron and Telix Announce Strategic Radiopharma Collaboration</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/regeneron-and-telix-announce-strategic-radiopharma-collaboration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/regeneron-and-telix-announce-strategic-radiopharma-collaboration-1</guid>
      <pubDate>Mon, 13 Apr 2026 10:30:00 GMT</pubDate>
      <description>Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody discovery/development platforms and oncology experience with Telix’s expertise in radiopharmaceutical development and manufacturing Telix to receive $40 million USD upfront for four initial programs with optionality to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion</description>
    </item>
    <item>
      <title>Telix and Regeneron Announce Radiopharma Collaboration</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-and-regeneron-announce-radiopharma-collaboration</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-and-regeneron-announce-radiopharma-collaboration</guid>
      <pubDate>Mon, 13 Apr 2026 02:48:06 GMT</pubDate>
      <description>Telix and Regeneron Announce Radiopharma Collaboration</description>
    </item>
    <item>
      <title>FDA Accepts NDA for TLX101-Px (Pixclara)</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/fda-accepts-nda-for-tlx101-px-pixclara</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/fda-accepts-nda-for-tlx101-px-pixclara</guid>
      <pubDate>Fri, 10 Apr 2026 02:47:05 GMT</pubDate>
      <description>FDA Accepts NDA for TLX101-Px (Pixclara)</description>
    </item>
    <item>
      <title>Telix Strengthens Board with Additional Director Appointments</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-strengthens-board-with-additional-director-appointments</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-strengthens-board-with-additional-director-appointments</guid>
      <pubDate>Wed, 08 Apr 2026 22:58:00 GMT</pubDate>
      <description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026[1], as part of Board expansion and succession planning:</description>
    </item>
    <item>
      <title>Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/q1-2026-strong-revenue-growth-and-tx-pipeline-advancement</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/q1-2026-strong-revenue-growth-and-tx-pipeline-advancement</guid>
      <pubDate>Tue, 07 Apr 2026 02:49:07 GMT</pubDate>
      <description>Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement</description>
    </item>
    <item>
      <title>Telix Appoints David Gill as Non-Executive Director</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-appoints-david-gill-as-non-executive-director-11</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-appoints-david-gill-as-non-executive-director-11</guid>
      <pubDate>Wed, 01 Apr 2026 23:53:00 GMT</pubDate>
      <description>MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years’ e</description>
    </item>
    <item>
      <title>Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-selects-iba-cycloner-kiube-to-support-manufacturing-expansion-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-selects-iba-cycloner-kiube-to-support-manufacturing-expansion-in-the-us</guid>
      <pubDate>Fri, 20 Mar 2026 06:00:00 GMT</pubDate>
      <description>Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies</description>
    </item>
    <item>
      <title>Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-resubmits-nda-to-fda-for-pixclara-brain-cancer-imaging</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-resubmits-nda-to-fda-for-pixclara-brain-cancer-imaging</guid>
      <pubDate>Mon, 16 Mar 2026 01:40:04 GMT</pubDate>
      <description>Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging</description>
    </item>
    <item>
      <title>Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-resubmits-nda-to-us-fda-for-tlx101-px-pixclarar-brain-cancer-imaging-candidate</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-resubmits-nda-to-us-fda-for-tlx101-px-pixclarar-brain-cancer-imaging-candidate</guid>
      <pubDate>Sun, 15 Mar 2026 21:26:00 GMT</pubDate>
      <description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®[1], Floretyrosine F 18 or 18F-FET), an investigational PET[2] imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.</description>
    </item>
    <item>
      <title>ProstACT Global Phase 3 (Part 1) Results Presentation</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-results-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-results-presentation</guid>
      <pubDate>Tue, 10 Mar 2026 01:45:06 GMT</pubDate>
      <description>ProstACT Global Phase 3 (Part 1) Results Presentation</description>
    </item>
    <item>
      <title>ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-achieves-primary-objectives</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/prostact-global-phase-3-part-1-achieves-primary-objectives</guid>
      <pubDate>Tue, 10 Mar 2026 01:45:06 GMT</pubDate>
      <description>ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives</description>
    </item>
    <item>
      <title>Investor Education Webinar</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/investor-education-webinar</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/investor-education-webinar</guid>
      <pubDate>Sun, 01 Mar 2026 22:56:00 GMT</pubDate>
      <description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) invites investors to join a webinar with key opinion leaders to discuss a physician&apos;s perspective on innovations in PSMA-PET/CT imaging for prostate cancer.</description>
    </item>
    <item>
      <title>Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging</title>
      <link>https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-joins-forces-with-university-hospital-essen-on-promise-pet-optimizing-patient-management-through-ai-enabled-psma-pet-imaging</link>
      <guid isPermaLink="true">https://6ix.com/company/telix-pharmaceuticals-ltd/news/telix-joins-forces-with-university-hospital-essen-on-promise-pet-optimizing-patient-management-through-ai-enabled-psma-pet-imaging</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 GMT</pubDate>
      <description>MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI). PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET is a multi-center, prospective, observational, non-interventional registry study designed t</description>
    </item>
  </channel>
</rss>